Formulary Search Results for: CALCIUM AND VITAMIN D
5.3.1.4 Other retrovirals - View Category
Restrictions:
The use in combination with other antiretroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age is restricted to use by HIV specialists.
6.5.2 Posterior pituitary hormones and antagonists - View Category
Restrictions:
Desmopressin tablets are restricted to use in patients unable to use intramuscular preparations. Intravenous desmopressin is restricted to use in specialist haemophilia centres.
Prescribing Notes:
- Used for treatment of diabetes insipidus, primary nocturnal enuresis and postoperative polyuria or polydipsia. Due to the high level of adverse reactions, desmopressin nasal spray is no longer indicated for primary nocturnal enuresis. Oral formulations should be considered as an alternative.
- For use in the symtomatic treatment of nocturia due to idiopathic nocturnal polyuria see section 7.4.2
13.5.3 Drugs affecting the immune response - View Category
Restrictions:
Restricted to specialist use in accordance with local guidelines in patients with the following indications:
Psoriasis
Patients with moderate to severe psoriasis who have failed to respond to standard systemic therapies, are intolerant to, or have a contra-indication to these treatments.
Hidradenitis suppurativa (HS)
Adult patients with active moderate to severe HS for whom adalimumab is contraindicated or otherwise unsuitable, including those who have failed to respond or have lost response to prior adalimumab treatment.
9.1.8 Drugs for other blood disorders - View Category
Restrictions:
Restricted to use under the advice of the national paroxysmal nocturnal haemoglobinuria (PNH) service as add-on to ravulizumab or eculizumab for the treatment of adult patients with PNH who have residual haemolytic anaemia.
13.5.3 Drugs affecting the immune response - View Category
Restrictions:
Restricted to specialist use in the treatment of:
- Moderate to severe plaque psoriasis in accordance with local guidelines in patients who have failed to respond to conventional systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have contra-indications to these treatments.
- Moderate to severely active Crohn's disease in patients 16 year of age and older, who have an inadequate response to, lost response to, or where intolerant to conventional therapy, or if such therapies are not advisable.
13.5.3 Drugs affecting the immune response - View Category
Restrictions:
Restricted to specialist use for moderate to severe atopic dermatitis in patients who have had an
inadequate response to at least one conventional systemic immunosuppressant such as ciclosporin, or
in whom such treatment is considered unsuitable.
Prescribing Notes:
Following a MHRA review in April 2023, the risk of increased incidence of malignancy, major adverse cardiovascular events (MACE), serious infections, venous thromboembolism (VTE) and mortality, when compared to those treated with tumour necrosis factor (TNF)-alpha inhibitors, were are considered a class effects across JAK inhibitors used for chronic inflammatory disorders and therefore it is advised to avoid prescribing these medicines unless there are no suitable alternatives in patients with the following risk factors:
- age 65 years or older
- current or past long-time smoking
- other risk factors for cardiovascular disease or malignancy
Please see further details of the review here.
12.1.1 Otitis externa - View Category
9.6.2 Vitamin B group - View Category
5.1.7 Some other antibacterials - View Category
Restrictions:
Restricted to use on the advice of local microbiologists and infectious disease specialists only in the following situations:
- in accordance with OPAT service clinical management pathway for second-line use or when meticillin-resistant Staphylococcus aureus (MRSA) infection is suspected AND when the patient is initially hospitalised due to ABSSSI, requires intravenous antibiotics, but is eligible for early discharge as soon as their medical condition does not require further inpatient treatment.
Prescribing Notes:
Please note: this is a PROTECTED ANTIBIOTIC (see policy here) and relevant paper work should be completed.
5.1.7 Some other antibacterials - View Category
Restrictions:
Restricted to specialist initiation by a microbiologist or specialist in infectious diseases. Restricted to use in patients not responding to or intolerant of a glycopeptide, or those with microbiological cultures which indicate glycopeptide resistance.
Prescribing Notes:
Please note, this is a PROTECTED ANTIBIOTIC (see policy here) and relevant paper work should be completed.
For daptomycin dosing in adults click here